Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for skeletal metastases

01.07.2002


Norwegian and Swedish researchers have developed a new type of internal radiation therapy for cancer that has spread to skeletal tissue. Experience from an early patient test is optimistic, according to a report being presented at the 18th International Cancer Congress in Oslo this week.



Many patients with advanced breast, prostate or lung cancer experience metastasis to skeletal tissue. This is often a source of pain and suffering.

Exterior irradiation and medication, including radioactive substances injected into the bloodstream, can retard cancer growth in skeletal tissue, but now a new radium isotope may offer a new and better alternative. The first tests on Norwegian and Swedish patients are currently in progress, and the experience thus far gives grounds for optimism.


Isotopes are incorporated into skeletal tissue
Special cells called osteoclasts help build up skeletal tissue and try to help repair damaged tissue in areas affected by cancer. When small doses of the element radium are injected into the bloodstream, the osteoclasts will incorporate radium instead of calcium. This means radium can be incorporated into skeletal tissue, where it will give off radiation that kills cancer cells.

"Today, this type of ’internal’ radiation therapy is usually based on pharmaceuticals that contain strontium. Strontium has a scope of six to seven millimetres, meaning it can damage bone marrow and impair the production of new blood cells. But radium223 has a scope of just two millimetres. This leads us to believe that bone marrow will incur less damage", states Senior Medical Officer Lise Balteskard, PhD, University Hospital of Northern Norway. Along with physicians at the Norwegian Cancer Hospital, she has treated the first Norwegian patients with radium223.

The element radium is found in many isotope variants with different half-lives and scopes. The new isotope is a radium223 isotope developed at the Studsvik reactor in Sweden. In addition to the short scope of the radiation, it has a half-life of only 11 days.

Pain relief

In animal trials, this new isotope had good results on breast cancer that had spread to skeletal tissue. The animals lived longer and some were cured. (Cancer Research, June 2002). Experience from the first study on 20 Norwegian and Swedish patients indicates that many were able to use a lower dose of painkillers. This indicates that the treatment is effective.

"This is a phase 1 study where we are testing different doses to determine which dose we can administer without too many side effects. First and foremost, we are examining blood platelets and white cells in the blood to see whether their production is affected. The patients have advanced cancer. It was promising that many of them could take a lower dose of painkillers, as it implies improved quality of life. However, a phase 2 study is required to perform imaging, determine whether there is any reduction in malignant tissue, and systematically examine pain relief and survival", explains Balteskard.

"Is it possible that this new radium isotope might offer a cure for skeletal metastasis?"

"We believe this treatment might be administered the first time a tumour spreads to skeletal tissue, and that it might inhibit metastases. This would have an effect on pain and quality of life and could increase survival. It is still too early to tell whether such treatment might offer a cure if administered early enough", adds Balteskard.

Abstract P 459 in Poster Session 1 refers to the Norwegian-Swedish study on radium 223.
For more information, see the abstract from the symposium: Skeletal metastases, Monday, 08.45, inter alia in 15, Serafini, which will give an overview of bone-seeking radioactive isotopes for use in cancer treatment

Hanna Hånes | EurekAlert!
Further information:
http://www.kreft.no/

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>